Analyst evaluations for Humana (NYSE:HUM) over the past three months show a mix of bullish and bearish perspectives, with a notable decline in the average 12-month price target to $455.6, a 16.72% decrease. Recent actions by analysts include lowering price targets and maintaining ratings, reflecting adjustments to market conditions and company performance. Humana, a major private health insurer in the U.S., has shown solid revenue growth of 17.93% as of December 31, 2023, but faces challenges with a net margin of -2.04% and a high debt-to-equity ratio of 0.74.